Member Info for Chazzy2

http://www.proactiveinvestors.co.uk/companies/stocktube/7742/angle-plc-boss-absolutely-delighted-with-results-from-pelvic-mass-study-7742.html Excellent RNS. Andrew Newland upbeat and very positive about the future for Parsortix as always.

Great RNS today. The case for Parsortix keeps getting better. Big article in the Daily Mail today about the breakthrough also!

FDA approval will firstly be in metastatic breast cancer, but clinical trials will also need to be successfully completed in that application before sales can commence. The ovarian cancer clinical trial data will (if successful) validate the Parsortix system for clinical use, so that clinical sales can then start in Europe. When FDA approval is given in the ovarian cancer application sales can also start in the US. The machines are being sold currently into the research market, not yet the much bigger clinical market.

I agree with you Scot, this is a slow burner but completely worth waiting for. Definitely not a jam tomorrow share. Angle is gaining real traction now. Key opinion leaders worldwide are testing the Parsortix system and publishing key data validating the efficacy of the system. FDA approval is getting ever closer now, research sales are picking up and the first clinical trial data will be out in the next few weeks. A positive result will really put Angle on the map which will drive further sales and promote further clinical trials. Angle has a great leading position in the $20 billion dollar liquid biopsy market. It's worth listening to the recent webcast for a detailed but really encouraging update on the progress of Angle. AN presents really well as always.

https://www.clinicaltrials.gov/ct2/show/NCT03058289?term=intensity+therapeutics&rank=1 sorry - wrong link!

http://www.lse.co.uk/ShareChat.asp?ShareTicker=SALV&share=salvarx_grp_plc Seen it now. Took a bit of digging though!

Where does it say that no results are expected until July 2018? I must have missed that bit. I would have thought it would be sooner than that.

http://www.businesswire.com/news/home/20170404005049/en/Intensity-Therapeutics-Reports-INT230-6-Induces-Protective-T-Cell Good news that they are now recruiting for the trials.

https://www.youtube.com/watch?v=MS4_FaslkPs

I think we may be seeing the Jim Mellon effect today. SALV was one of his picks for going long at his Master Investor speech. Investors are taking notice.

Great to hear SALV presenting at the MI show today. It was a fairly short presentation of only 10 minutes but strongly reinforced the investment case. I didn't catch the name of the presenter (it wasn't Ian Walters unfortunately, who gave an excellent presentation last year) but he stated that SALV hopes to make some more investments this year, with the aim of phasing the investments so as to bring at least one drug to clinical trials each year. Huge market of $80 billion by 2020. Jim Mellon obviously a big fan still as he sat in the front row!

http://www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/27337/northland-capital-partners-view-on-the-city-immupharma-plc-salvarx

$5 million should last long enough until there is sufficient human trial data to strike a deal with a big pharma.

I think the point of the loan notes of up to $5 million is the fact that it negates any need for raising capital via a placing. If anything it is an great endorsement by the board of Salvarx of its future success.

http://www.proactiveinvestors.co.uk/columns/northland-capital-partners-view-on-the-city/27182/northland-capital-partners-view-on-the-city-premier-african-minerals-ltd-salvarx-savannah-resources-plc-27182.html

Good news about the clinical trials for Intensity starting soon. I imagine what has really moved the sp today is the formal announcement by SALV itself rather than news being inaccurately quoted via other sources, which always leads to speculation and uncertainty. Keep up the news flow SALV.

Yes I noticed the article too. It would have been nice if we had read about it through SALV however. Still, at least things are happening now.

Well that's really helpful of Jim!! What gets me is the fact that both Salvarx and Intensity presented at the Master Investor show 2016 with very upbeat presentations, suggesting clinical trials were just round the corner. I appreciate clinical trials take time and get delayed sometimes but it would be nice if the board just kept shareholders in the picture. Maybe we'll get some sort of update with interim results soon.

I have tried to contact SALV regarding the lack of updates. The website hasn't been updated in months and doesn't even include Intensity Therapautics. Any emails I send bounce back. There does not seem to be any way to contact the management. Very poor communications with shareholders. Not impressed at all.

No news for three months now. What is going on??